ValuEngine cut shares of Akorn (NASDAQ:AKRX) from a hold rating to a sell rating in a research report released on Friday.
AKRX has been the subject of a number of other reports. TheStreet cut Akorn from a c- rating to a d rating in a report on Friday, May 4th. Zacks Investment Research cut Akorn from a hold rating to a sell rating in a report on Wednesday, January 24th. BidaskClub cut Akorn from a sell rating to a strong sell rating in a report on Friday, April 13th. Piper Jaffray set a $34.00 price target on Akorn and gave the stock a hold rating in a report on Wednesday, March 7th. Finally, William Blair reissued a hold rating on shares of Akorn in a report on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. The company presently has a consensus rating of Hold and an average price target of $28.20.
Akorn opened at $14.25 on Friday, Marketbeat reports. The company has a quick ratio of 3.37, a current ratio of 4.64 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 8.71, a P/E/G ratio of 1.15 and a beta of 1.71. Akorn has a twelve month low of $14.01 and a twelve month high of $14.34.
Akorn Company Profile
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.